MedTrace Logo

Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye

NCT02846571 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2026-03-12

No results posted yet for this study

Summary

The intervention in this trial is intraocular islet transplantation. A single dose of 1000 - 3000 Islet Equivalents (IEQ)/kg recipient body weight (BW) will be infused into the anterior chamber of the eye through a self-sealing incision in the peripheral cornea. The procedure is projected to take approximately 20-30 minutes. Transplant recipients in this study will receive localized maintenance immunosuppression via topical application of eye-drops.

Conditions

Interventions

BIOLOGICAL

Human Pancreatic Islet Transplantation

Human pancreatic islet transplantation in the eye anterior chamber of legally blind type 1 or type 2 diabetes patients with and without insulin-dependence

Sponsors & Collaborators

  • Diabetes Research Institute Foundation

    collaborator OTHER

  • Bascom Palmer Eye Institute

    collaborator OTHER

  • Midhat H. Abdulreda

    lead OTHER

Principal Investigators

  • Midhat H Abdulreda, Ph.D. · University of Miami

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-05
Primary Completion
2026-12-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02846571 on ClinicalTrials.gov